Five-year survival for stage 3 lung cancer ranges from about 13% to 36%, depending on the sub-stage and type. That’s a wide range, and where you fall within it depends on several factors: whether the cancer is non-small cell or small cell, how far it has spread within the chest, which treatments you receive, and whether your tumor carries certain genetic changes. Newer treatments, particularly immunotherapy given after chemoradiation, have pushed these numbers higher than they were even a decade ago.
Survival Rates by Sub-Stage
Stage 3 non-small cell lung cancer (NSCLC), which accounts for roughly 85% of lung cancers, is divided into three sub-stages based on how far the tumor has spread to nearby lymph nodes and structures. The differences in outlook between them are significant:
- Stage 3A: About 36% of patients survive five years. The cancer has spread to lymph nodes on the same side of the chest as the tumor, but not to the opposite side.
- Stage 3B: About 26% survive five years. The cancer has reached lymph nodes on the opposite side of the chest or has grown into nearby structures like the heart lining or major airways.
- Stage 3C: About 13% survive five years. The tumor has invaded chest wall structures and spread to lymph nodes on the opposite side.
These are overall averages across all treatment types. Individual outcomes can be considerably better or worse depending on your health, the specific treatment plan, and how the cancer responds.
Small Cell Lung Cancer Is Different
Small cell lung cancer (SCLC) grows faster and is staged differently. When it’s still confined to one side of the chest (called “limited stage,” which roughly overlaps with stage 3), median survival is 15 to 20 months. That means half of patients live longer than that, and half live shorter.
Smoking status has a measurable effect on SCLC outcomes. In one study of 284 limited-stage patients, the two-year survival rate was 47% for former smokers and never-smokers, 57% for those who quit at or after diagnosis, and 35% for those who continued smoking. Quitting at any point appears to improve the odds.
How Immunotherapy Has Changed the Outlook
The most important recent advance for stage 3 NSCLC is the addition of immunotherapy after chemoradiation. In the landmark PACIFIC trial, patients who received an immune checkpoint drug after completing chemoradiation had a five-year survival rate of 42.9%, compared to 33.4% for those who received chemoradiation alone. That’s roughly a 10-percentage-point improvement, which represents a meaningful shift for a cancer that has historically been difficult to treat.
This approach has become standard care for most stage 3 NSCLC patients whose tumors don’t shrink enough to be surgically removed. The immunotherapy is given as an infusion every two to four weeks for up to a year after chemoradiation is complete.
Genetic Mutations That Affect Prognosis
Some lung cancers carry specific genetic changes that make them vulnerable to targeted drugs. Two of the most important are EGFR mutations and ALK rearrangements, which are more common in non-smokers and younger patients.
For patients with these mutations who receive targeted therapy, survival times are notably longer. Median survival is about 37 months for EGFR-mutated cancers and 55 months for ALK-rearranged cancers. The survival curves for these patients show something encouraging: they appear to flatten out after about six years, suggesting that a subset of patients may achieve very long-term survival. At the six-year mark, about 20% of EGFR-mutated patients and 46% of ALK-rearranged patients were still alive.
Not all stage 3 tumors are tested for these mutations, particularly if the initial plan is chemoradiation rather than systemic therapy. If you haven’t been told about your tumor’s genetic profile, it’s worth asking your oncologist whether molecular testing has been done or would be useful in guiding your treatment.
Surgery vs. Chemoradiation
For some stage 3A patients, surgery combined with chemotherapy and radiation (called trimodal therapy) is an option. For more advanced stage 3 disease, particularly when cancer has spread to lymph nodes on the opposite side of the chest, definitive chemoradiation without surgery is the usual approach.
The question of surgery versus chemoradiation alone is nuanced. In a large matched study of patients with the most advanced lymph node involvement, surgery carried higher risk in the first six months, likely due to surgical complications and recovery. But after that initial period, patients who had surgery showed significantly better long-term survival. This pattern held across multiple analyses, though the decision depends heavily on your overall fitness, the specific location of the tumor, and the surgical team’s experience.
Recurrence Risk and Timeline
Even after successful treatment, stage 3 lung cancer carries a substantial risk of coming back. In one study of stage 3 NSCLC patients treated with chemoradiation, 37% experienced recurrence within the first year. For those who recurred early, the median time to recurrence was about six months after treatment. For those who recurred later, the median was roughly 28 months.
This is why follow-up after treatment is intensive, typically involving CT scans every few months for the first two to three years, then gradually spacing out. The first two years are the highest-risk window. Patients who remain cancer-free past the five-year mark have substantially lower odds of late recurrence, though it’s never zero.
What Influences Individual Outcomes
Statistics describe populations, not individuals. Several factors shift your personal outlook in one direction or another. General physical fitness matters: patients who are active and have fewer other health conditions tolerate treatment better and tend to have better outcomes. Weight loss before or during treatment is a negative prognostic sign, so maintaining nutrition is a practical priority.
How the tumor responds to initial treatment is one of the strongest predictors of long-term survival. Patients whose tumors shrink significantly with chemoradiation have a meaningfully better outlook than those whose tumors remain stable or grow. Your oncologist will typically assess response with imaging partway through treatment and again after it’s complete.
Age alone is less predictive than overall health. Older patients in good condition often do just as well as younger patients with the same stage, while younger patients with serious comorbidities may face tougher odds. The biology of the individual tumor, including growth rate, genetic features, and how it interacts with the immune system, plays a larger role than age in determining how things unfold.